Effect of IL-10 on formation of foam cell induced by ox-LDL

Effect of IL-10 on formation of foam cell induced by ox-LDL

Abstract

Atherosclerosis is a chronic disease that causes various cardiovascular complications. It has been realized that cellular and humoral immunity plays crucial roles in atherogenic lesion formation. In this study the effects of lipopolysaccharide (LPS) and interleukin-10 (IL-10) on the formation of foam cells during the early stages of atherosclerosis have been investigated. Macrophage was induced by phorbol myristate acetate (PMA) treatment on THP-1 cells. The cells were further stimulated by ox-LDL, ox-LDL plus LPS, ox-LDL plus IL-10 and LPS. By using an oil red O staining technique, the formation of foam cells was evaluated by lipid granules formation in the cells. The ratio of foam cell formation was increased from (9.77 ± 1.70)% to (16.27 ± 2.27)% after 24 h stimulation with ox-LDL, and the increase was observed with incubating time. The foam cells were significantly increased in the presence of LPS in a dose-dependent manner. The maximum increase of about 40% was observed. However, the significant elevation by LPS was abrogated when IL-10 was added. These results indicated that IL-10 can effectively prevent the formation of foam cells induced by ox-LDL with or without LPS. This study demonstrates that ox-LDL can cause foam cell formation from macrophages in vitro. LPS can significantly accelerate this event. IL-10, an anti-inflammatory cytokine, can inhibit the effect of ox-LDL and LPS. These results indicate that inflammatory effects in blood vessels can speed up foam cell formation. The inhibitive effect of IL-10 is an important factor for delaying atherosclerosis processes.

参考文献

1. Glass C K, Witztum J L . Atherosclerosis. the roadahead.Cell, 2001, 104(4): 503–516. doi:10.1016/S0092‐8674(01)00238‐0
2. Hansson G K . Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol, 2001, 21(12): 1876–1890. doi:10.1161/hq1201.100220
3. Frostegard J . Autoimmunity,oxidized LDL and cardiovascular disease. Autoimmun Rev, 2002, 1(4): 223–237. doi:10.1016/S1568‐9972(02)00059‐9
4. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher A M . Interleukin-10 serum Levelsand systemic Endothelial vasoreactivity in patients with coronaryartery disease. J Am Coll Cardiol, 2004, 44(1): 44–49. doi:10.1016/j.jacc.2004.02.054
5. Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Marín J L, Betriu A, Sanz G . Elevation of serum levels of the anti-inflammatorycytokine interleukin-10 and decreased risk of coronary events in patientswith unstable angina. Am Heart J, 2002, 144(5): 811–817
6. Heesche C, Dimmeler S, Hamm C W, Fichtlscherer S, Boersma E, Simoons M, Zeiher A . Serum levelof the anti-inflammatory cytokine interleukin-10 is an important prognosticdeterminant in patients with acute coronary syndromes. Circulation, 2003, 107(16): 2109–2114. doi:10.1161/01.CIR.0000065232.57371.25
7. Von Der Thusen J H, Kuiper J, Fekkes M L, Vos P D, Van Berkel T J C and Biessen E A L . Attenuation of atherogenesisby systemic and local adenovirus-mediated gene transfer of interleukin-10in LDLr-/-mice. FASEB J, 2001, 15(14): 2730–3732
8. Pinderski L J, Fischbein M P, Subbanagounder G, Fishbein M C, Kubo N, Cheroutre H, Curtiss L K, Berliner J A, Boisvert W A . Overexpression of interleukin-10 by activated T lymphocytesinhibits atherosclerosis in LDL receptor-deficient mice by alteringlymphocyte and macrophage phenotypes. CircRes, 2002, 90(10): 1064–1071. doi:10.1161/01.RES.0000018941.10726.FA
9. Rubic T, Lorenz R L . Downregulated CD36 and ox-LDLuptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atheroscleroticmechanisms of interleukin-10. CardiovascRes, 2006, 69(2): 527–535. doi:10.1016/j.cardiores.2005.10.018
10. Zerbinatti C, Gore R W . Uptake of modified low-densitylipoproteins alters actin distribution and locomotor forces in macrophages. Am J Physiol Cell Physiol, 2003, 284(2): 555–561
11. Murphy J E, Tedbury P R, Homer-Vanniasinkam S, Warlker J, Ponnambalam S . Biochemistry and cell biologyof mammalian scavenger receptors. Atherosclerosis, 2005, 182(1): 1–15. doi:10.1016/j.atherosclerosis.2005.05.015
12. Ohashi R, Mu H, Yao Q, Chen C . Atherosclerosis:immunopathogenesis and immunotherapy. MedSci Monit, 2004, 10(11): RA255–260
13. Greaves D, Gordon S . Recent insights into thebiology of macrophage scavenger receptors. J lipid Res, 2005, 46(1): 11–20. doi:10.1194/jlr.R400011‐JLR200
14. Lucas A D, Greaves D R . Atherosclerosis: role ofchemokines and macrophages. Expert RevMol Med, 2001, 3(25): 1–18. doi:10.1017/S1462399401003696
15. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob M P, Michel J B, Feldman L J . Effects of interleukin-10on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovas Res, 2001, 49(4): 882–890. doi:10.1016/S0008‐6363(00)00287‐X
16. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, Groux H, Tedgui A, Mallat Z . Leukocyte-Derived Interleukin 10 Is Required for ProtectionAgainst Atherosclerosis in Low-Density Lipoprotein Receptor KnockoutMice. Arterioscler Thromb Vasc Biol, 2004, 24(8): 1474–1478. doi:10.1161/01.ATV.0000134378.86443.cd
17. Raychaudhuri B, Fisher C J, Farver C F, Malur A, Drazba J, Kavuru M S, Thomassen M J . Interleukin 10 (IL-10)-mediatedinhibition of inflammatory cytokine production by human alveolar macrophages. Cytokine, 2000, 12(9): 1348–1355. doi:10.1006/cyto.2000.0721
18. Shanley T P, Vasi N, Denenberg A . Regulation of chemokine expression by IL-10 in lung inflammation. Cytokine, 2000, 12(7): 1054–1064. doi:10.1006/cyto.1999.0655
19. Amico G D, Frascaroli G, Bianchi G, Transidico P, Doni A, Vecchi A, Sozzani S, Allavena P, Mantovani A . Uncoupling of inflammatory chemokine receptors by IL-10:generation of functional decoys. NatureImmunlogy, 2000, 1(5): 387–391. doi:10.1038/80819
20. Peiser L, Winther M, Makepeace K, Hollinshead M, Coull P, Plested J, Kodama T, Moxon E, Gordon S . Theclass A macrophage scavenger receptor is a major pattern recognitionreceptor for nesseria meningititdis which is independent of lipopolysaccharideand not required for secretory responses. Infect Immun, 2002, 70(10): 5346–5354. doi:10.1128/IAI.70.10.5346‐5354.2002
21. van Berkel T, Out R, Hoekstra M, Kuiper J, Biessen E, van Eck M . Scavengerreceptors: friend or foe in atherosclerosis. Curr Opin Lipidol, 2005, 16(5): 525–535. doi:10.1097/01.mol.0000183943.20277.26
22. Mallat Z, Besnard S, Duriez M, Deeluze V, Emmanuel F Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A . Protective role of IL-10 in atherosclerosis. Circ Res, 1999, 85(8): e 17–24